

At a Glance: To optimize and expedite the enduring task of reevaluating clinical significance, Sunquest Mitogen partnered with MolecularMatch to incorporate **Molecular Assertions** into their LIMS system. **Molecular Assertions automates scientific rationale tiering** using new standards and guidelines published by AMP, CAP and ASCO. This includes scientific rationale that supports treatment recommendations of existing clinical data standards.

Molecular Assertions: Supporting Targeted Treatment Recommendations Keeping up with Regulatory Standards and Evidence in Today's Growing Cancer Genomics Industry

Core Benefits

- Optimize and standardize your clinical reporting with **validated assertions**.
- Reduce time and effort associated with **frequent reevaluation** of publications and determining their level of evidence.
- Pathologists and physicians in tumor boards quickly and consistently make evidence based **molecularly targeted decisions**.
- Gain confidence by complying with standards and guidelines that suit your Lab.
- Easily update to **new data standard changes** for defining levels of evidence.
- **Quickly access tiered, evidence based treatment options within the Mitogen Portal via a simple URL.**



CONDITION

THERAPEUTIC

MUTATION

CLINICAL
SIGNIFICANCE

BIOMARKER
CLASS

DIRECTION

EVIDENCE

GUIDELINE
TIER



COLLEGE of AMERICAN
PATHOLOGISTS



Molecular Assertions simplify somatic variant interpretation and reporting for targeted cancer treatments by leveraging standards and guidelines to quickly define clinical significance and actionability in conjunction with supporting evidence.

Molecular Assertions Powered by MolecularMatch

- Decoupled tiering structure to customize levels of evidence
- Provide more accurate and relevant assertions by collaborating with trusted academic institutions
- Developing proprietary assertions based on scientific literature
- Ultimately, Molecular Assertions improves efficiencies and maintains consistency across the industry with standards and guidelines compliance.

"Cancer genomics is a rapidly evolving field; therefore, the clinical significance of any variant in therapy, diagnosis, or prognosis should be reevaluated on an ongoing basis."

A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
The Journal of Molecular Diagnostics, Vol. 19, No. 1, January 2017

2018 Molecular Assertions Advances:

**at least 350 genes
over 10 cancer types
20,000 or more variants**